Literature DB >> 31088961

Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.

Peng Sang1, Min Zhang2, Yan Shi1, Chunpu Li1,3,4, Sami Abdulkadir1, Qi Li5,4, Haitao Ji6, Jianfeng Cai7.   

Abstract

The rational design of α-helix-mimicking peptidomimetics provides a streamlined approach to discover potent inhibitors for protein-protein interactions (PPIs). However, designing cell-penetrating long peptidomimetic scaffolds equipped with various functional groups necessary for interacting with large protein-binding interfaces remains challenging. This is particularly true for targeting β-catenin/BCL9 PPIs. Here we designed a series of unprecedented helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B Cell Lymphoma 9 (BCL9). Our studies show that sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9 and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL9 PPIs, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, our enzymatic stability studies demonstrate the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential. This work represents not only an example of helical sulfono-γ-AApeptides that mimic α-helix and disrupt protein-protein interactions, but also an excellent example of potent, selective, and cell-permeable unnatural foldameric peptidomimetics that disrupt the β-catenin/BCL9 PPI. The design of helical sulfono-γ-AApeptides may lead to a new strategy to modulate a myriad of protein-protein interactions.

Entities:  

Keywords:  B-cell lymphoma 9; inhibitors; protein–protein interactions; α-helix mimetics; β-catenin

Year:  2019        PMID: 31088961      PMCID: PMC6561201          DOI: 10.1073/pnas.1819663116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.

Authors:  Justin T Ernst; Jorge Becerril; Hyung Soon Park; Hang Yin; Andrew D Hamilton
Journal:  Angew Chem Int Ed Engl       Date:  2003-02-03       Impact factor: 15.336

Review 2.  Inhibition of protein-protein interactions using designed molecules.

Authors:  Andrew J Wilson
Journal:  Chem Soc Rev       Date:  2009-07-27       Impact factor: 54.564

3.  The proteolytic stability of 'designed' beta-peptides containing alpha-peptide-bond mimics and of mixed alpha,beta-peptides: application to the construction of MHC-binding peptides.

Authors:  David F Hook; Pascal Bindschädler; Yogesh R Mahajan; Radovan Sebesta; Peter Kast; Dieter Seebach
Journal:  Chem Biodivers       Date:  2005-05       Impact factor: 2.408

4.  Crystal structure of a beta-catenin/BCL9/Tcf4 complex.

Authors:  James Sampietro; Caroline L Dahlberg; Uhn Soo Cho; Thomas R Hinds; David Kimelman; Wenqing Xu
Journal:  Mol Cell       Date:  2006-10-20       Impact factor: 17.970

5.  Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.

Authors:  Steven A Kawamoto; Adriana Coleska; Xu Ran; Han Yi; Chao-Yie Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2012-01-24       Impact factor: 7.446

6.  The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Authors:  Yingzi Wang; Andrei V Krivtsov; Amit U Sinha; Trista E North; Wolfram Goessling; Zhaohui Feng; Leonard I Zon; Scott A Armstrong
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

7.  Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.

Authors:  Shungo Adachi; Takafumi Jigami; Toshio Yasui; Tetsuhiro Nakano; Susumu Ohwada; Yoshihiro Omori; Sumio Sugano; Bisei Ohkawara; Hiroshi Shibuya; Tsutomu Nakamura; Tetsu Akiyama
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.

Authors:  Steven A Kawamoto; Andrea D Thompson; Adriana Coleska; Zaneta Nikolovska-Coleska; Han Yi; Shaomeng Wang
Journal:  Biochemistry       Date:  2009-10-13       Impact factor: 3.162

9.  Helical aromatic oligoamide foldamers as organizational scaffolds for photoinduced charge transfer.

Authors:  Martin Wolffs; Nicolas Delsuc; Dirk Veldman; Vân Anh Nguyên; René M Williams; Stefan C J Meskers; René A J Janssen; Ivan Huc; Albertus P H J Schenning
Journal:  J Am Chem Soc       Date:  2009-04-08       Impact factor: 15.419

10.  The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.

Authors:  Marc de la Roche; Jesper Worm; Mariann Bienz
Journal:  BMC Cancer       Date:  2008-07-15       Impact factor: 4.430

View more
  23 in total

1.  Rational Design and Synthesis of Right-Handed d-Sulfono-γ-AApeptide Helical Foldamers as Potent Inhibitors of Protein-Protein Interactions.

Authors:  Peng Sang; Yan Shi; Pirada Higbee; Minghui Wang; Sami Abdulkadir; Junhao Lu; Gary Daughdrill; Jiandong Chen; Jianfeng Cai
Journal:  J Org Chem       Date:  2020-08-02       Impact factor: 4.354

2.  Aggregation-Induced Emissive and Circularly Polarized Homogeneous Sulfono-γ-AApeptide Foldamers.

Authors:  Yan Shi; Peng Sang; Guangqiang Yin; Ruixuan Gao; Xiao Liang; Robert Brzozowski; Timothy Odom; Prahathees Eswara; Youxuan Zheng; Xiaopeng Li; Jianfeng Cai
Journal:  Adv Opt Mater       Date:  2020-04-20       Impact factor: 9.926

3.  Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.

Authors:  Sami Abdulkadir; Chunpu Li; Wei Jiang; Xue Zhao; Peng Sang; Lulu Wei; Yong Hu; Qi Li; Jianfeng Cai
Journal:  J Am Chem Soc       Date:  2021-12-30       Impact factor: 15.419

Review 4.  Targeting intracellular protein-protein interactions with macrocyclic peptides.

Authors:  Marina Buyanova; Dehua Pei
Journal:  Trends Pharmacol Sci       Date:  2021-12-13       Impact factor: 14.819

5.  Geared Toward Applications: A Perspective on Functional Sequence-Controlled Polymers.

Authors:  Cangjie Yang; Kevin B Wu; Yu Deng; Jingsong Yuan; Jia Niu
Journal:  ACS Macro Lett       Date:  2021-01-20       Impact factor: 6.903

6.  Structure-Activity Relationship of Peptide-Conjugated Chloramphenicol for Inhibiting Escherichia coli.

Authors:  Jiaqing Wang; Adrianna Shy; Difei Wu; Deani L Cooper; Jiashu Xu; Hongjian He; Wenjun Zhan; Shenghuan Sun; Susan T Lovett; Bing Xu
Journal:  J Med Chem       Date:  2019-11-12       Impact factor: 7.446

7.  Sulfono-γ-AApeptides as Helical Mimetics: Crystal Structures and Applications.

Authors:  Peng Sang; Yan Shi; Bo Huang; Songyi Xue; Timothy Odom; Jianfeng Cai
Journal:  Acc Chem Res       Date:  2020-09-17       Impact factor: 22.384

8.  Activation of E6AP/UBE3A-Mediated Protein Ubiquitination and Degradation Pathways by a Cyclic γ-AA Peptide.

Authors:  Bo Huang; Li Zhou; Ruochuan Liu; Lei Wang; Songyi Xue; Yan Shi; Geon Ho Jeong; In Ho Jeong; Sihao Li; Jun Yin; Jianfeng Cai
Journal:  J Med Chem       Date:  2022-01-19       Impact factor: 7.446

9.  Optimal anchoring of a foldamer inhibitor of ASF1 histone chaperone through backbone plasticity.

Authors:  Johanne Mbianda; May Bakail; Christophe André; Gwenaëlle Moal; Marie E Perrin; Guillaume Pinna; Raphaël Guerois; Francois Becher; Pierre Legrand; Seydou Traoré; Céline Douat; Gilles Guichard; Françoise Ochsenbein
Journal:  Sci Adv       Date:  2021-03-19       Impact factor: 14.136

10.  α/Sulfono-γ-AApeptide Hybrid Analogues of Glucagon with Enhanced Stability and Prolonged In Vivo Activity.

Authors:  Peng Sang; Hongxiang Zeng; Candy Lee; Yan Shi; Minghui Wang; Cong Pan; Lulu Wei; Chenglong Huang; Mingjun Wu; Weijun Shen; Xi Li; Jianfeng Cai
Journal:  J Med Chem       Date:  2021-09-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.